Pfizer/BioNTech Announces 95% Vaccine Efficacy

Pfizer and BioNTech announce Phase 3 trial results showing 95% efficacy against symptomatic COVID-19. The result far exceeds the FDA's minimum 50% threshold. Global stock markets surge. Moderna follows four days later with results showing 94.1% efficacy.